Valuation : Regeneron Pharmaceuticals, Inc.

Market Cap 8.27TCr 7.11TCr 6.69TCr 6.11TCr 11TCr 7,80400Cr 11TCr 79TCr 31TCr 4,00400Cr 31TCr 30TCr 12,89800Cr P/E 2026 *
19.2x
P/E 2027 * 16.4x
Enterprise Value 7.58TCr 6.52TCr 6.14TCr 5.6TCr 10TCr 7,15500Cr 11TCr 73TCr 28TCr 3,67100Cr 28TCr 28TCr 11,82700Cr EV / Sales 2026 *
4.48x
EV / Sales 2027 * 3.91x
Free-Float
71.06%
Yield 2026 *
0.47%
Yield 2027 * 0.54%
1 day-1.87%
1 week+4.22%
Current month+3.58%
1 month+7.69%
3 months+30.26%
6 months+8.21%
Current year+7.24%
1 week 779.08
Extreme 779.08
859.34
1 month 767.17
Extreme 767.17
859.34
Current year 591.52
Extreme 591.52
859.34
1 year 541
Extreme 541
859.34
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Sell

Executive/Senior Manager

-1,131 0.0011%
02/09/26 Exercice

Director

1,200 0.0012%
19/08/26 Exercice

General Counsel

33,583 0.0326%
Change 5-day change 1-year change 3-year change Capi.($)
-1.87%+4.22%+44.36%+0.58% 8.27TCr
-0.57%+1.27%-16.61%-35.57% 6.02TCr
-2.23%+5.48%+478.96%+33.09% 5.81TCr
-2.03%-2.62%-8.63%+27.87% 4.97TCr
-4.58%-2.73%+1.79%+159.87% 4.67TCr
-1.64%+1.07%+56.98%-17.07% 3.26TCr
-0.98%+1.91%+46.30%+100.30% 2.57TCr
-0.19%-4.74%-0.68%+194.68% 2.27TCr
-1.13%-2.45%+64.66%+108.24% 1.65TCr
+1.94%-9.84%-21.13%+779.37% 1.49TCr
Average -1.33%-0.83%+64.60%+135.14% 4.1TCr
Weighted average by Cap. -1.72%+0.49%+82.81%+69.62%

Financials

2026 *2027 *
Net sales 1.69TCr 1.46TCr 1.37TCr 1.25TCr 2.34TCr 1,59800Cr 2.35TCr 16TCr 6.28TCr 82TCr 6.35TCr 6.22TCr 2,64100Cr 1.84TCr 1.58TCr 1.49TCr 1.36TCr 2.55TCr 1,73900Cr 2.56TCr 18TCr 6.84TCr 89TCr 6.92TCr 6.77TCr 2,87400Cr
Net income 477.34Cr 410.75Cr 386.46Cr 353.03Cr 660.41Cr 45TCr 662.21Cr 4.57TCr 1.77TCr 23TCr 1.79TCr 1.75TCr 74TCr 544.54Cr 468.58Cr 440.86Cr 402.73Cr 753.39Cr 51TCr 755.44Cr 5.21TCr 2.02TCr 26TCr 2.04TCr 2TCr 85TCr
Net Debt -686.84Cr -591.02Cr -556.07Cr -507.97Cr -950.26Cr -65TCr -952.85Cr -6.57TCr -2.55TCr -33TCr -2.58TCr -2.52TCr -1,07200Cr -1.06TCr -908.16Cr -854.45Cr -780.54Cr -1.46TCr -1LCr -1.46TCr -10TCr -3.92TCr -51TCr -3.96TCr -3.88TCr -1,64700Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
04/26/04 $827.72 -1.87% 5,61,170
03/26/03 $843.47 -1.00% 4,96,255
02/26/02 $852.03 +3.42% 7,49,453
01/26/01 $823.82 +3.10% 6,82,806
31/26/31 $799.08 +0.62% 8,94,268
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
827.72USD
Average target price
840.43USD
Spread / Average Target
+1.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock